Today: 20 May 2026
Tesla stock ends 2025 lower as Musk charity share gift surfaces ahead of deliveries
2 January 2026
2 mins read

Tesla stock ends 2025 lower as Musk charity share gift surfaces ahead of deliveries

NEW YORK, January 1, 2026, 7:33 PM ET — Market closed.

  • Tesla last closed down 1.1% at $449.72 in the final session of 2025.
  • A filing showed CEO Elon Musk gifted 210,699 Tesla shares to charities as part of year-end tax planning.
  • Investors are watching for Tesla’s fourth-quarter delivery report expected Friday.

Tesla shares finished the last trading session of 2025 lower after a regulatory filing showed Chief Executive Elon Musk gifted 210,699 shares to charities at the end of December. The stock last closed down 1.1% at $449.72.

The disclosure matters now because Tesla enters 2026 with investor focus turning back to near-term demand signals, starting with its quarterly vehicle deliveries update expected Friday.

Those numbers are being watched closely as the electric-vehicle market gets more crowded and price competition remains intense, especially in China.

Wall Street’s regular session is shut on New Year’s Day and resumes normal hours on Friday, Jan. 2, according to the New York Stock Exchange holiday calendar.

In the Form 4 filing, Musk said the transfer was tied to “year-end tax planning” and that the recipient charities had indicated they had “no current intention to sell” the stock. The transaction date was Dec. 30. SEC

At Wednesday’s close, the gifted stake would be worth roughly $95 million, based on Reuters calculations from the closing price, though Tesla’s shares have been volatile into year-end.

Investors are also weighing Tesla’s sales trajectory against the pace set by Chinese rival BYD, which said 2025 electric-vehicle sales exceeded Tesla’s estimated total as it pushed overseas to offset tougher conditions at home.

Tesla is expected to report about 440,900 deliveries in the fourth quarter, down 11% from a year earlier, according to Bloomberg-compiled data cited by The Straits Times. The company has also published its own average of analyst estimates that implies a steeper decline, the report said.

“Tesla investors are focused on how the company might look five, 10, 15 years down the road,” Garrett Nelson, an equity analyst at CFRA Research, told The Straits Times, adding that the question is whether that patience holds as headwinds show up in the financials. The Straits Times

One demand headwind in the U.S. is the lapse of the federal clean-vehicle tax credit after Sept. 30, 2025, under IRS rules, removing a subsidy that had helped pull forward purchases earlier in the year.

Beyond deliveries, traders will be watching for signs Tesla can defend margins through pricing and mix, and whether enthusiasm around autonomy and robotics continues to outweigh weaker unit growth.

Before next session, the biggest known catalyst is the deliveries release, with investors looking for any gap versus expectations and for regional demand signals that could shape early-2026 sentiment.

Tesla has not yet posted an earnings date for its fourth-quarter results on its investor relations calendar, which showed its prior fourth-quarter results were released late January last year.

Macro catalysts that can move growth stocks are also stacking up in January, including the U.S. employment report on Jan. 9 and the December CPI report on Jan. 13, followed by the Federal Reserve’s Jan. 27-28 policy meeting.

Technically, traders are watching whether Tesla holds the $450 area after the year-end slide; a rebound would put the recent $458–$460 zone back in view as near-term resistance.

Stock Market Today

  • Roivant Sciences Q4 Loss Beats Estimates; Revenue Misses
    May 20, 2026, 9:59 AM EDT. Roivant Sciences Ltd. reported a fourth-quarter loss of $0.23 per share, better than the Zacks estimate of a $0.25 loss, marking an 8% positive earnings surprise. Revenue missed expectations, coming in at $28.93 million, down 11% from estimates but up from $27.38 million a year ago. Despite three out of four quarters beating EPS estimates recently, the company's shares have declined 4.5% year-to-date, underperforming the S&P 500's 10.4% rise. Earnings outlook remains cautious with a Zacks Rank #4 (Sell), suggesting expected near-term underperformance. Current consensus projects a loss of $0.21 per share next quarter on $56.64 million revenue and a fiscal year loss of $1.07 on $172.45 million. Industry outlook in medical-biomedical genetics also weighs on investor sentiment.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Coca-Cola stock (KO) sits near $70 as New Year’s Day shuts markets — what Wall Street watches next
Previous Story

Coca-Cola stock (KO) sits near $70 as New Year’s Day shuts markets — what Wall Street watches next

Pentagon awards Lockheed $328.5 million Taiwan contract for IR sensor pods as China drills escalate
Next Story

Pentagon awards Lockheed $328.5 million Taiwan contract for IR sensor pods as China drills escalate

Go toTop